Released Mar 17, 2014, after the close
10-K filed Mar 17, 2014, 76 days after period end · 0001390478-14-000016
Q4 2013 · 10-K
Revenue$1.44M$1.44M ±0.0% vs Q4 2012−33.7% vs Q3 2013
Net Income-$5.52M-$5.52M N/M vs Q4 2012N/M vs Q3 2013
EPS, diluted—
Gross Profit$1,229,000±0.0%
Operating Incomederived-$6,999,000—
Operating Cash Flowderived-$8,492,000N/M
Free Cash Flowderived-$8,258,000—
Margins · derived
Gross margin85.6%±0.0 pt vs Q4 2012
Operating margin-487.4%
Net margin-384.1%+986.2 pt vs Q4 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2013 | Q4 2012 | Q4 2011dderived from reported figures | Q4 2010dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.44M | $1.44M | — | — |
| Net Income | -$5.52M | -$19.68M | $1.59M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR